Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment

[1]  Antonios Revythis,et al.  Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer , 2022, International journal of environmental research and public health.

[2]  Aruni Ghose,et al.  Applications of Proteomics in Ovarian Cancer: Dawn of a New Era , 2022, Proteomes.

[3]  Sidrah Shah,et al.  Non-Epithelial Ovarian Cancers: How Much Do We Really Know? , 2022, International journal of environmental research and public health.

[4]  S. Harper,et al.  Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy , 2021, Nature Communications.

[5]  C. Xiao,et al.  Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10 , 2021, World Journal of Surgical Oncology.

[6]  Mohamed H. Mahmoud,et al.  Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance , 2021, Cancers.

[7]  Kun Huang,et al.  C3AR1 mRNA as a Potential Therapeutic Target Associates With Clinical Outcomes and Tumor Microenvironment in Osteosarcoma , 2021, Frontiers in Medicine.

[8]  Xiangliang Yang,et al.  Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles , 2021, Nature communications.

[9]  S. Xia,et al.  Dual inhibition of EGFR and IL-6-STAT3 signalling by miR-146b: a potential targeted therapy for epithelial ovarian cancer , 2021, Journal of enzyme inhibition and medicinal chemistry.

[10]  Xiaoyu Liu,et al.  High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[11]  Shibo Zhang,et al.  Macrophage-mediated vascular permeability via VLA4/VCAM1 pathway dictates ascites development in ovarian cancer. , 2020, The Journal of clinical investigation.

[12]  Zhiqiang Li,et al.  C3, C3AR1, HLA-DRA, and HLA-E as potential prognostic biomarkers for renal clear cell carcinoma , 2020, Translational andrology and urology.

[13]  Bao-qin Liu,et al.  m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. , 2020, Biochimica et biophysica acta. Molecular cell research.

[14]  G. Calin,et al.  Bone morphogenetic protein 7 promotes resistance to immunotherapy , 2020, Nature Communications.

[15]  Yufei Wang,et al.  Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy , 2020, Cancers.

[16]  Hong Yang,et al.  CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner , 2020, Theranostics.

[17]  A. Martins Filho,et al.  Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms , 2020, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[18]  Qun Zhou,et al.  Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology , 2020, Molecular Cancer.

[19]  X. Ju,et al.  A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients , 2020, Frontiers in Oncology.

[20]  Yuquan Zhang,et al.  Cyclin H predicts the poor prognosis and promotes the proliferation of ovarian cancer , 2020, Cancer Cell International.

[21]  C. Luo,et al.  Estrogen enhances the proliferation and migration of ovarian cancer cells by activating transient receptor potential channel C3 , 2020, Journal of Ovarian Research.

[22]  Fang Wang,et al.  The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation , 2020, Nucleic acids research.

[23]  K. Tucker,et al.  Docosahexaenoic acid (DHA), an omega-3 fatty acid, inhibits tumor growth and metastatic potential of ovarian cancer. , 2020, American journal of cancer research.

[24]  C. Shao,et al.  Harnessing tumor-associated macrophages as aids for cancer immunotherapy , 2019, Molecular Cancer.

[25]  L. Kwak,et al.  Targeting myeloid-derived suppressor cells for cancer immunotherapy , 2018, Cancer Immunology, Immunotherapy.

[26]  Yan Kang,et al.  Tregs: Where We Are and What Comes Next? , 2017, Front. Immunol..

[27]  Yi Luo,et al.  Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells. , 2017, International journal of oncology.

[28]  Hidde L. Ploegh,et al.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion , 2014, Nature.

[29]  G. Weiner,et al.  Complement in monoclonal antibody therapy of cancer , 2014, Immunologic research.

[30]  K. Baggerly,et al.  Autocrine Effects of Tumor-Derived Complement , 2014, Cell reports.

[31]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..